Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
FibroBiologics, Inc. ( (FBLG) ) has issued an announcement.
FibroBiologics, Inc. announced the closure of the second $5 million tranche under the Standby Equity Purchase Agreement with YA II PN, LTD., part of a $25 million financing plan. This funding is expected to support general corporate purposes and demonstrates FibroBiologics’ ongoing efforts to strengthen its financial position and advance its clinical programs.
More about FibroBiologics, Inc.
FibroBiologics, Inc., based in Houston, is a clinical-stage biotechnology company focused on developing treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds over 160 patents, both issued and pending, across various clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
YTD Price Performance: -92.30%
Average Trading Volume: 159,221
Technical Sentiment Consensus Rating: Strong Buy
Find detailed analytics on FBLG stock on TipRanks’ Stock Analysis page.
